Guangdong Kanghua Healthcare Group (3689) Fundamentals 2026 — P/E 5.4x, Revenue Analysis | SniperIQ
Guangdong Kanghua Healthcare Group (3689) is a CN-listed Healthcare company in Medical - Care Facilities with a market capitalization of HK$605M, trading at HK
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Guangdong Kanghua Healthcare Group's market cap?
Guangdong Kanghua Healthcare Group (3689) has a market capitalization of approximately HK$605M, trading at HK
What is Guangdong Kanghua Healthcare Group's P/E ratio?
Guangdong Kanghua Healthcare Group's trailing twelve-month P/E ratio is 5.4x, with a price-to-book (P/B) of 0.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Guangdong Kanghua Healthcare Group?
Guangdong Kanghua Healthcare Group runs a net profit margin of 4.9%, a gross margin of 18.2%, and an operating margin of 5.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Guangdong Kanghua Healthcare Group generate?
Guangdong Kanghua Healthcare Group reported revenue of ¥2.0B for fiscal year 2025, with net income of ¥97M and earnings per share (EPS) of 0.29. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Guangdong Kanghua Healthcare Group pay a dividend?
Guangdong Kanghua Healthcare Group offers a trailing dividend yield of about 10.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Guangdong Kanghua Healthcare Group financially healthy?
Guangdong Kanghua Healthcare Group carries a debt-to-equity ratio of 0.22x and a current ratio of 1.35x, with a market beta of 0.40. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Guangdong Kanghua Healthcare Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Guangdong Kanghua Healthcare Group (3689) the key facts are: market cap HK$605M, P/E 5.4x, revenue ¥2.0B, 52-week range 1.35-2.3. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Guangdong Kanghua Healthcare Group's full fundamentals live
Get Guangdong Kanghua Healthcare Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.